Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encochleated amphotericin B - Matinas BioPharma

Next Previous
Drug Profile

Encochleated amphotericin B - Matinas BioPharma

Alternative Names: CAmB; MAT-2203

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Aquarius Biotechnologies; Matinas BioPharma
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryptococcosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cryptococcosis
  • Phase II Candidiasis; Mycoses; Vulvovaginal candidiasis
  • Preclinical Aspergillosis
  • No development reported Visceral leishmaniasis

Most Recent Events

  • 27 Mar 2024 Encochleated amphotericin B - Matinas BioPharma is available for licensing as of 27 Mar 2024.
  • 27 Mar 2024 Matinas Biopharma plans the phase III ORALTO trial in Aspergillosis in the US, Europe, South America, Middle East, and Asia Pacific (PO) in 2H of 2024
  • 27 Mar 2024 Preclinical development in Aspergillosis is ongoing in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top